Six Month DMPA
Description: A single subcutaneous injection of medroxyprogesterone acetate injectable suspension, 150mg/mL, currently approved for intramuscular use every 3 months.
Product Details
Duration: 6 months plus at least 2 week grace period
Regimen:
Dose: 150 mg
Active Pharmaceutical Ingredient (API):
Inactive material: polyethylene glycol 3350; polysorbate 80; sodium chloride; methylparaben; propylparaben; water for injection
Status Details
Began discovery in: 2010
Status Details: - As of 2017, in active follow up of Phase I study.
- As of 2017, in active follow up of Phase I study.
Additional Information
References: Halpern V, et al. (2015) Towards the development of a longer-acting injectable contraceptive: past research and current trends. Contraception.
Halpern V, et al. (2015) Towards the development of a longer-acting injectable contraceptive: past research and current trends. Contraception.